Lantheus Medical Imaging has signed an agreement with NTP Radioisotopes, a subsidiary of the South African Nuclear Energy Corporation (NECSA), to manufacture and supply Lantheus with an ongoing volume of molybdenum-99 (Mo-99).
Under the terms of this agreement, the North Billerica, Mass.-based Lantheus said it will receive a supply of Mo-99 at regular intervals from NTP. NTP has, in turn, partnered with Belgian radiochemical producer IRE to co-supply the Lantheus requirement and thereby maximize security of ongoing regular supplies of Mo-99 to Lantheus.
"Partnering with NTP Radioisotopes as a reliable supplier of Mo-99 will provide us with expanded access within a limited supply chain," said Don Kiepert, president and CEO at Lantheus. "This partnership will bring our complementary skill sets and commitment to quality and reliability together to ensure patients have uninterrupted, timely access to needed medical imaging procedures that can diagnose life-threatening conditions such as heart disease and cancer."